
FDA approves groundbreaking pancreatic cancer drug Rasonque
The story in brief
The FDA approved Rasonque, a groundbreaking pancreatic cancer drug, for patients with advanced disease who have tried prior treatments. The drug targets a mutation causing uncontrolled cell growth and has side effects like rash and vomiting. Over 2,000 patients have received it under an expanded access program, with a monthly cost of $39,800 before insurance. In trials, patients lived twice as long with Rasonque plus chemotherapy.